News Stories

Jul, 2023

Novartis received FDA approval for a label update that will allow for use of Leqvio ® (inclisiran) in certain patients at high risk of cardiovascular (CV) disease. This broader population allows for earlier Leqvio treatment in patients with elevated low-density lipoprotein cholesterol (LDL-C) and CV risk factors, such as diabetes and hypertension, who are at increased risk of atherosclerotic cardiovascular disease (ASCVD), beyond the previously approved ASCVD and heterozygous familial hypercholesterolemia (HeFH) patient population.

0
No votes yet
Name: NLA News
Nov, 2024

Call for Nominations is open for the National Lipid Association Board of Directors and Chapter officers and will be extended until 5 pm ET on February 15, 2025.

To submit a nomination and for more information on the process, visit lipid.org/nominate.

0
No votes yet
Name: NLA News